logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical reports key development in dual gene therapy program

The heath sciences company said in a press release that it has identified at least four novel small interfering RNA (siRNA) constructs

Gene illustration
The identified sequences are a fundamental piece in the gene therapy approach, according to PreveCeutical

PreveCeutical Medical Inc (CSE:PREV) (OTCMKTS:PRVCF) reported Monday a key development in its dual gene therapy program.

The Vancouver-based health sciences company said in a press release that it has identified at least four novel small interfering RNA (siRNA) constructs that target the gene of interest, while reducing its expression by at least 80% compared with a random siRNA control sequence. The gene therapy approach may have applications for diabetes and obesity. 

READ: PreveCeutical Medical unveils promising findings from non-addictive analgesics program

The advance, according to PreveCeutical, sets the company on a path to creating a series of lead siRNA constructs, with the goal of employing innovative design strategies that enhance gene targeting specificity and biostability while maintaining exceptional gene silencing capacity.

“This is an important development in our dual gene therapy program,” Dr Harendra Parekh, the company’s chief research officer, said in a statement.

"The identified sequences are a fundamental piece in the gene therapy approach to potential applications for diabetes and obesity, representing the 'medicine' component of the proposed therapy.”

Shares of PreveCeutical fetched C$0.06 in Friday’s Canadian trading and US$0.04 on the OTC markets.

Last week, the company said it had completed a study of peptides to develop as non-addictive painkillers, with promising results.

Contact Dennis Fitzgerald at [email protected]

Quick facts: PreveCeutical Medical Inc.

Price: 0.055 CAD

CSE:PREV
Market: CSE
Market Cap: $21.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Preveceutical announces successful preliminary evaluation of...

Preveceutical (CSE:PREV-OTCQB: PRVCF) President Mak Jawadeker joined Steve Darling from Proactive Vancouver on Skype to discuss the company successfully completing the design, synthesis and preliminary evaluation of key peptides from its scorpion venom-derived peptide research and development...

on 15/11/19

2 min read